Trial ID or NCT#

NCT00725361

Status

NOT RECRUITING

Purpose

This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.

Official Title

A Pilot Study to Evaluate the Efficacy of Ambrisentan in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis.

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Lorinda Chung
Rheumatologist, Immunologist
Professor of Medicine (Immunology and Rheumatology) at the Palo Alto Veterans Affairs Health Care Center

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM